- Home
- PLX vs RANI Comparison
PLX vs RANI Comparison
Compare PLX & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- RANI
- Stock Information
- Founded
- PLX 1993
- RANI 2012
- Country
- PLX Israel
- RANI United States
- Employees
- PLX N/A
- RANI N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- RANI Medicinal Chemicals and Botanical Products
- Sector
- PLX Health Care
- RANI Health Care
- Exchange
- PLX Nasdaq
- RANI Nasdaq
- Market Cap
- PLX 79.4M
- RANI 73.8M
- IPO Year
- PLX 1998
- RANI 2021
- Fundamental
- Price
- PLX $1.68
- RANI $2.04
- Analyst Decision
- PLX
- RANI Strong Buy
- Analyst Count
- PLX 0
- RANI 5
- Target Price
- PLX N/A
- RANI $11.80
- AVG Volume (30 Days)
- PLX 439.0K
- RANI 645.6K
- Earning Date
- PLX 11-14-2024
- RANI 11-14-2024
- Dividend Yield
- PLX N/A
- RANI N/A
- EPS Growth
- PLX N/A
- RANI N/A
- EPS
- PLX N/A
- RANI N/A
- Revenue
- PLX $45,667,000.00
- RANI N/A
- Revenue This Year
- PLX N/A
- RANI N/A
- Revenue Next Year
- PLX $88.94
- RANI N/A
- P/E Ratio
- PLX N/A
- RANI N/A
- Revenue Growth
- PLX N/A
- RANI N/A
- 52 Week Low
- PLX $0.82
- RANI $1.90
- 52 Week High
- PLX $1.90
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- PLX 74.56
- RANI 38.86
- Support Level
- PLX $1.14
- RANI $2.32
- Resistance Level
- PLX $1.75
- RANI $2.10
- Average True Range (ATR)
- PLX 0.12
- RANI 0.16
- MACD
- PLX 0.05
- RANI -0.05
- Stochastic Oscillator
- PLX 87.29
- RANI 5.97
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.